CHADI CALARGE to Risperidone
This is a "connection" page, showing publications CHADI CALARGE has written about Risperidone.
Connection Strength
7.248
-
Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251.
Score: 0.543
-
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
Score: 0.520
-
CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915.
Score: 0.512
-
Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol. 2016 06; 26(5):471-7.
Score: 0.462
-
Iron homeostasis during risperidone treatment in children and adolescents. J Clin Psychiatry. 2015 Nov; 76(11):1500-5.
Score: 0.452
-
Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 06; 5:e652.
Score: 0.450
-
Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry. 2015 May; 76(5):607-13.
Score: 0.436
-
The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatr. 2015 Jun; 166(6):1449-54.e1.
Score: 0.435
-
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2014 Apr; 24(3):120-9.
Score: 0.405
-
Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013 Mar; 23(2):101-9.
Score: 0.376
-
Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr. 2012 Dec; 161(6):1010-5.
Score: 0.358
-
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90.
Score: 0.345
-
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9.
Score: 0.330
-
Iron status in toddlerhood predicts sensitivity to psychostimulants in children. J Atten Disord. 2012 May; 16(4):295-303.
Score: 0.319
-
A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47.
Score: 0.305
-
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec; 19(6):320-7.
Score: 0.300
-
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May; 19(5):373-82.
Score: 0.288
-
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009 Apr; 19(2):101-9.
Score: 0.286
-
Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755.
Score: 0.126